Zidovudine pharmacokinetics
Sanz, S.; Altisent, C.; Montoro, J.B.; Pou, L.
Medicina Clinica 101(18): 717
1993
ISSN/ISBN: 0025-7753 PMID: 8114530 Document Number: 409116
Document emailed within 1 workday
Related Documents
Mays, D.C.; Dixon, K.F.; Balboa, A.; Pawluk, L.J.; Bauer, M.R.; Nawoot, S.; Gerber, N. 1991: A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats Journal of Pharmacology and Experimental Therapeutics 259(3): 1261-1270Lopez-Anaya, A.; Unadkat, J.D.; Schumann, L.A.; Smith, A.L. 1990: Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate Journal of Acquired Immune Deficiency Syndromes 3(11): 1052-1058
Dolin, R.; Amato, D.A.; Fischl, M.A.; Pettinelli, C.; Beltangady, M.; Liou, S.H.; Brown, M.J.; Cross, A.P.; Hirsch, M.S.; Hardy, W.D. 1995: Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group Archives of Internal Medicine 155(9): 961-974
Lertcheewakarn, P.; Tongprasert, F. 2014: A comparison of maternal anemia between HIV infected pregnant women receiving zidovudine-based and zidovudine-free highly active Antiretroviral therapy (HAART) Journal of the Medical Association of Thailand 97(4): 361-368
Staszewski, S.; Keiser, P.; Montaner, J.; Raffi, F.; Gathe, J.; Brotas, V.; Hicks, C.; Hammer, S.M.; Cooper, D.; Johnson, M.; Tortell, S.; Cutrell, A.; Thorborn, D.; Isaacs, R.; Hetherington, S.; Steel, H.; Spreen, W. 2001: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial JAMA 285(9): 1155-1163
Katlama, C.; Ingrand, D.; Loveday, C.; Clumeck, N.; Mallolas, J.; Staszewski, S.; Johnson, M.; Hill, A.M.; Pearce, G.; McDade, H. 1996: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. a randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group JAMA 276(2): 118-125
Gartland, M. 2001: AVANTi 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients Antiviral Therapy 6(2): 127-134
Zijenah, L.S.; Kadzirange, G.; Rusakaniko, S.; Kufa, T.; Gonah, N.; Tobaiwa, O.; Gwanzura, C.; Matsikire, E.; Katzenstein, D.A. 2006: A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe Central African Journal of Medicine 52(1-2): 1-8
Goodgame, J.C.; Pottage, J.C.; Jablonowski, H.; Hardy, W.D.; Stein, A.; Fischl, M.; Morrow, P.; Feinberg, J.; Brothers, C.H.; Vafidis, I.; Nacci, P.; Yeo, J.; Pedneault, L. 2000: Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team Antiviral Therapy 5(3): 215-225
Moolasart, P.; Likanonsakul, S. 2002: The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children Southeast Asian Journal of Tropical Medicine and Public Health 33(2): 280-287
Brion, N.; Contrepois, A.; Carbon, C. 1983: From serum pharmacokinetics to extravascular pharmacokinetics of antibiotics. Importance of protein binding Presse Medicale 12(5): 293-296
Paxton, J.W. 1981: Elementary pharmacokinetics in clinical practice 4: genetic, environmental and age influences on pharmacokinetics New Zealand Medical Journal 94(697): 423-425
Daniel, W.; Syrek, M.; Janczar, L.; Boksa, J. 1995: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine Polish Journal of Pharmacology 47(2): 127-136
De Mey, C.; Scharpe, S.; De Bock, R.; Bossaert, L. 1981: Predictive pharmacokinetics of amikacin using actually measured and assumed parameters, applied in 1-compartment linear pharmacokinetics Archives Internationales de Pharmacodynamie et de Therapie 253(2): 323-324
Chocarro Martínez, A.; González López, A.; Chimeno Viñas, M.; Villafañe, C. 1996: Overdose of zidovudine Revista Clinica Espanola 196(1): 60-61
Shenton, J. 1992: HIV, AIDS, and zidovudine Lancet 339(8796): 806
Paradis, J.; Calis, K.A. 1994: Zidovudine-associated myopathy American Journal of Hospital Pharmacy 51(24): 3026-3028
Urso, P.; Majekodunmi, M.J.; Cobb, J.R.; Lemon, T.; Etemadi, A.A.; Jones, T.M.; Wirsiy, Y.G. 1995: Zidovudine as an immunomodulatory agent Cellular and Molecular Biology 41(Suppl): S103-S112
Kouzan, S.; Nebout, T. 1991: Zidovudine (AZT). Current state of the development Annales de Medecine Interne 142(6): 444-455
Masquelier, B.; Lemoigne, E.; Pellegrin, I.; Douard, D.; Sandler, B.; Fleury, H.J. 1993: Primary infection with zidovudine-resistant HIV New England Journal of Medicine 329(15): 1123-1124